Journal article
Potential coverage of the 4CMenB vaccine against invasive serogroup B Neisseria meningitidis isolated from 2009 to 2013 in the Republic of Ireland
- Abstract:
-
Neisseria meningitidis is a common cause of bacterial meningitis in children and young adults worldwide. The 4CMenB vaccine (Bexsero), developed to combat meningococcal serogroup B (MenB) disease, contains subcapsular antigens that may induce immunity against strains of N. meningitidis, regardless of serogroup. Owing to differential levels of expression and peptide diversity in vaccine antigens across meningococcal strains, the meningococcal antigen typing system (MATS) was developed to estim...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
GlaxoSmithKline Biologicals SA
More from this funder
Bibliographic Details
- Publisher:
- American Society for Microbiology Publisher's website
- Journal:
- Clinical and Vaccine Immunology Journal website
- Volume:
- 3
- Issue:
- 4
- Pages:
- e00196-18
- Publication date:
- 2018-08-22
- Acceptance date:
- 2018-07-23
- DOI:
- EISSN:
-
1556-679X
- ISSN:
-
1556-6811
Item Description
Terms of use
- Copyright holder:
- Mulhall et al
- Copyright date:
- 2018
- Notes:
-
Copyright © 2018 Mulhall et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
- Licence:
- CC Attribution (CC BY)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record